肿瘤细胞治疗研究
英文原题：Anbalcabtagene Autoleucel: First Approval.
Anbalcabtagene autoleucel（RIMQARTO）是一种 CAR T 疗法，其包含的 CAR T 细胞同时下调 PD-1 和 TIGIT，以减轻 T 细胞耗竭。
Anbalcabtagene autoleucel（RIMQARTO）是一种CAR T疗法，其CAR T细胞同时下调PD-1和TIGIT以减轻T细胞耗竭。该疗法由Curocell Inc.开发，用于治疗弥漫性大B细胞淋巴瘤、急性淋巴细胞白血病和自身免疫性疾病，并于2026年4月在韩国获得首次批准。本文总结了anbalcabtagene autoleucel在开发过程中的里程碑，这些里程碑促成了其首次获批用于治疗成人经2线全身治疗后复发或难治性弥漫性大B细胞淋巴瘤和原发性纵隔大B细胞淋巴瘤。
Anbalcabtagene autoleucel (RIMQARTO ) is a CAR T therapy that includes CAR T cells with dual PD-1 and TIGIT downregulation to mitigate T cell exhaustion. It is being developed by Curocell Inc. for the treatment of diffuse large B-cell lymphoma, acute lymphoblastic leukaemia and autoimmune diseases, which received its first approval in April 2026 in South Korea. This article summarizes the milestones in the development of anbalcabtagene autoleucel leading to this first approval for the treatment of relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults following 2 lines of systemic therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
